title: [Potential of a GLP-1 receptor agonist combined with basal insulin in the treatment of type 2 diabetes].
abstract: The complex pathophysiology of type 2 diabetes and its natural evolution, characterized by a progressive loss of glucose control due to the exhaustion of insulin secretion, lead to consider new complementary therapeutic options. Even at the insulin-requiring stage, the addition of a glucagon-like peptide-1 (GLP-1) receptor agonist is beneficial. Besides their incretinomimetic activity (which may decrease with the loss of beta-cell mass/function), GLP-1 receptor agonists reduce glucagon secretion, slow down gastric emptying and diminish appetite through a central effect. These combined effects permit to improve glucose control, while reducing daily insulin doses, together with less weight gain (or even weight loss) and generally less hypoglycaemia. Fixed insulin glargine-lixisenatide and insulin degludec-liraglutide are currently in development.
authors.forename: André J
authors.initials: AJ
authors.lastname: Scheen
authors.forename: Nicolas
authors.initials: N
authors.lastname: Paquot
mesh_terms: D001066:Appetite / Q000187:drug effects; D001835:Body Weight / Q000187:drug effects; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000503:physiopathology; D004359:Drug Therapy, Combination; D005746:Gastric Emptying / Q000187:drug effects; D005934:Glucagon / Q000187:drug effects; D000067757:Glucagon-Like Peptide-1 Receptor; D006728:Hormones; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D007328:Insulin / Q000627:therapeutic use*; D018027:Receptors, Glucagon / Q000819:agonists*; D016896:Treatment Outcome
chemical_list: C000593833:GLP1R protein, human; D000067757:Glucagon-Like Peptide-1 Receptor; D006728:Hormones; D007004:Hypoglycemic Agents; D007328:Insulin; D018027:Receptors, Glucagon; D005934:Glucagon